cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.